Vaccine(s) were received on 11/07/2016
At the time of vaccination, patient was : 68 of age
Patient sex : M
Reaction was life threatening?: N
Patient eventually recovered from reaction ?: N
Patient eventually died?: Y

The following Data for this patients HISTORY is available: Medical History/Concurrent Conditions: Pain

The following Data for this patients ALLERGIES is available: [ ]

Description of adverse reaction: Based on information received on 15 Nov 2017, the following information has been amended: vaccine preferred name changed from "INFLUENZA QUADRIVALENT RECOMBINANT VACCINE" to "INFLUENZA VACCINE". Initial unsolicited case received from a consumer (patient wife) via other company Astellas Pharma under the MFR control number: 2016US015482 on 15 Nov 2017. This case involves 67-year-old male patient who was vaccinated with a dose of INFLUENZA VACCINE and a dose of PNEUMOCOCCAL VACCINE (Batch numbers, expiry date, dose, dose in series, route and site of administration were not reported for both the vaccines) on 07 Nov 2016. The patient also started treatment with 160 mg and 120 mg dose of XTANDI (Manufacturer: Astellas Pharma) (Batch numbers reported as 1539683PC and 1543982PC, expiry date not reported) daily once orally from an unknown dates for prostate cancer with metastasis and metastatic castrate resistant prostate cancer. (It was reported as patient had no changes after starting the drug and patient was enroll

Vaccine(s) associated with report# 739780

Type	Name	Manufacturer	Vaccine LOT #	Dose Series	ROUTE	Site
FLUX	INFLUENZA (SEASONAL) (NO BRAND NAME)	UNKNOWN MANUFACTURER		0	SYR	UN
PPV	PNEUMO (NO BRAND NAME)	UNKNOWN MANUFACTURER		0	SYR	UN

Symptoms(s) associated with report# 739780

Arthralgia
Contusion
Death
Decreased appetite
Depression
Fatigue
Headache
Hot flush
Injection site pain
Limb discomfort